Data from French named patient program of quizartinib in relapsed/refractory acute myeloid leukemia.

.1713</td></tr><tr><td> 1-year OS in allografted patients (%)</td><td char="(">44</td><td char="(">56</td><td char="(">21</td><td char="." HT <table><thead><tr><td /><td>R/R AML Quizartinib monotherapy <italic>N</italic> = 57</td><td>Previous exposure to midostaurin <italic>N</italic> = 27</td><td>No previous exposure to midostaurin <italic>N</italic> = 30</td><td><italic>p</italic></td></tr></thead><tbody valign="top"><tr><td>Age (years)</td><td char="(" /><td char="(" /><td char="(" /><td char=".">0 /></tr><tr><td> Median in allografted patients (months)</td><td char="(">7</td><td char="(">NR</td><td char="(">6.4</td><td char=".">0 /></tr><tr><td>AML status at quizartinib initiation, <italic>n</italic> (%)</td><td char="(" /><td char="(" /><td char="(" /><td char=".">0. [Extracted from the article]